A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)

NCT03988036 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Trastuzumab Biosimilar ABP 980
DRUG: Pertuzumab

Sponsor

West German Study Group

Collaborators

[object Object]
[object Object]